Tadalafil: Complete Canadian Research Guide (2026)

Quick answer (if you only read one paragraph)

Tadalafil is a long-acting PDE5 inhibitor with a 17.5-hour elimination half-life that distinguishes it from sildenafil (4 hours) and vardenafil (4 to 5 hours). Two dosing patterns are published in the clinical literature: 2.5 to 5 mg daily for steady-state plasma concentration, or 10 to 20 mg as-needed for an activity window of approximately 36 hours after a single dose. The side-effect profile is dominated by headache, flushing, and a tadalafil-specific back-pain pattern attributable to PDE11 cross-affinity. Tadalafil is Schedule F in Canada. Elite Bio Supply ships tadalafil for research compound only, not for human consumption.

Table of contents

1. What is tadalafil?
2. Mechanism: PDE5 inhibition
3. Pharmacokinetics: the 17.5h half-life
4. Dosing: 2.5/5/10/20 mg
5. Tadalafil vs sildenafil
6. Side-effect profile
7. BPH/LUTS use case
8. Drug interactions and contraindications
9. Regulatory status in Canada
10. Sourcing and quality verification
11. Frequently asked questions
12. References

---

What is tadalafil?

Tadalafil is an orally active selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for hydrolysing cyclic guanosine monophosphate (cGMP) in the smooth muscle of the corpus cavernosum, prostatic and bladder tissue, and the pulmonary vasculature. It was originally developed by ICOS Corporation in partnership with Eli Lilly under the brand name Cialis, and received its first regulatory approval from the U.S. Food and Drug Administration in 2003 for the treatment of erectile dysfunction (ED). It was the third PDE5 inhibitor to reach the market, after sildenafil (Viagra, Pfizer, 1998) and vardenafil (Levitra, Bayer, 2003). According to PubMed-indexed literature, tadalafil’s pharmacological profile differs from earlier PDE5 inhibitors primarily in its elimination half-life and isoenzyme selectivity, both of which translate into clinically distinct dosing strategies (Corbin and Francis, 2002, PMID 12166544).

In the years following its initial approval, tadalafil’s indication set expanded. In 2009 it received an additional label for once-daily low-dose use in ED, marking the first PDE5 inhibitor approved for steady-state dosing. In 2011 it was approved in the United States for the treatment of signs and symptoms of benign prostatic hyperplasia (BPH), with the same once-daily 5 mg dose used to treat ED also approved for lower urinary tract symptoms (LUTS) associated with BPH. A separate brand (Adcirca, also sold by Eli Lilly) was approved at higher doses for the treatment of pulmonary arterial hypertension (PAH).

For Canadian researchers, tadalafil is the most extensively studied long-acting PDE5 inhibitor. The clinical evidence base spans pharmacokinetic modeling, dose-ranging trials, head-to-head comparisons with sildenafil and vardenafil, BPH/LUTS pivotal trials, post-radiotherapy ED trials, and pooled long-term safety analyses. This research guide synthesizes the published literature relevant to laboratory and in vitro research applications. Nothing on this page is medical advice, and tadalafil is supplied by Elite Bio Supply for research use only.

Mechanism: PDE5 inhibition

The pharmacological target of tadalafil is phosphodiesterase type 5, an isoform of the cyclic nucleotide phosphodiesterase superfamily that selectively hydrolyses cyclic guanosine monophosphate (cGMP) into guanosine 5′-monophosphate (5′-GMP). cGMP is a second messenger downstream of nitric oxide (NO) signalling. In the corpus cavernosum, neuronal NO synthase activity in cavernous nerves and endothelial NO synthase in the cavernous endothelium produce NO, which activates soluble guanylate cyclase (sGC) to convert GTP into cGMP. cGMP, in turn, activates protein kinase G (PKG) and downstream effectors that lower intracellular calcium, relax smooth muscle, and permit blood inflow into the cavernosal sinusoids. Without active hydrolysis of cGMP by PDE5, smooth-muscle relaxation persists for the duration of plasma drug concentration above its inhibitory threshold (Corbin and Francis, 2002, PMID 12166544).

Tadalafil’s potency at PDE5 is in the low nanomolar range. According to PubMed, comparative IC50 measurements using radioimmunoassay against human recombinant PDE isozymes have placed tadalafil at approximately 2.35 nM for PDE5, in the same range as sildenafil at 5.22 nM (Wang et al., 2013, PMID 23937247, DOI).

The clinically relevant story is not raw potency. It is selectivity. The eleven mammalian phosphodiesterase isoforms differ in tissue distribution and substrate, and a PDE5 inhibitor’s clinical safety profile reflects how cleanly it discriminates between PDE5 and the other ten isoforms.

Two cross-reactivities matter for clinical practice:

• PDE6 is expressed in retinal photoreceptor outer segments and participates in phototransduction. Sildenafil and vardenafil have measurable PDE5/PDE6 cross-affinity, which is the molecular basis for transient blue-tinged vision and impaired blue-yellow discrimination reported by some users. Tadalafil’s selectivity for PDE5 over PDE6 is roughly an order of magnitude higher, and visual side effects are correspondingly less prevalent.
• PDE11 is expressed in skeletal muscle, prostate, testis, salivary gland, and pituitary tissue. Tadalafil has the highest PDE5/PDE11 cross-reactivity of the three originator PDE5 inhibitors, and PDE11 inhibition is the leading molecular hypothesis for the back pain and myalgia signal that distinguishes tadalafil from sildenafil and vardenafil in the adverse-event literature (Kayık et al., 2017, PMID 28150511, DOI).

This selectivity story is the reason the three drugs share a class effect (smooth-muscle relaxation in the cavernosum) but diverge in side-effect texture: sildenafil tends toward visual artifacts at peak concentration, tadalafil tends toward back pain at peak concentration, and vardenafil sits between them. None of the three has measurable PDE3 affinity, which is what would make the class problematic in cardiovascular co-administration.

Pharmacokinetics: the 17.5h half-life

The single feature that defines tadalafil’s clinical character is its elimination half-life. According to PubMed-indexed pharmacokinetic data, tadalafil’s apparent elimination half-life in healthy adults is approximately 17.5 hours, compared with approximately 4 hours for sildenafil and 4 to 5 hours for vardenafil. After a single oral dose, plasma concentrations remain above the threshold for clinically meaningful PDE5 inhibition for approximately 36 hours, which is the basis for the colloquial “weekend pill” framing of on-demand tadalafil in clinical literature (Porst et al., 2009, PMID 19756466, DOI).

A few additional pharmacokinetic features inform research design.

Time to maximum plasma concentration (T_max). Tadalafil reaches peak plasma concentration approximately 2 hours after oral administration. This is slower than sildenafil and vardenafil (30 to 60 minutes), reflecting differences in absorption kinetics. The slower onset has practical implications for protocols that require timing the dose ahead of an activity window.

Bioavailability. Tadalafil’s absolute bioavailability has not been published by the manufacturer, but its clinical-effect bioavailability is described as high and notably stable. Unlike sildenafil and vardenafil, tadalafil’s absorption is not meaningfully affected by food, including high-fat meals. In practical terms, a researcher does not need to time tadalafil around fasting or post-prandial windows.

Volume of distribution. Tadalafil’s volume of distribution is approximately 63 to 75 L, indicating moderate extravascular distribution. Plasma protein binding is approximately 94 percent.

Metabolism and elimination. Tadalafil is metabolized predominantly by hepatic CYP3A4 to a methylcatechol metabolite that is glucuronidated to an inactive conjugate. Approximately 36 percent of an oral dose is excreted in urine and 61 percent in feces, with both routes carrying primarily the inactive metabolite. The CYP3A4 dependency is the molecular basis for several drug-drug interaction warnings, discussed in the drug interactions section below.

The half-life translates directly into two clinical dosing patterns. The following comparison summarizes the four PDE5 inhibitors that have reached widespread regulatory approval.

Drug	Apparent half-life	T_max (single dose)	Food sensitivity
Tadalafil	17.5 h	~2 h	None
Sildenafil	4 h	30 to 60 min	Reduced absorption with high-fat meal
Vardenafil	4 to 5 h	30 to 60 min	Reduced absorption with high-fat meal
Avanafil	5 to 7 h	15 to 30 min	Mild

For a daily-dosed protocol, the long half-life means tadalafil reaches steady-state plasma concentration in approximately 5 days (5 half-lives). For washout, the same arithmetic applies in reverse: full clearance from plasma after the last dose requires approximately 3 to 4 days. This becomes operationally important when a researcher needs to switch dosing regimens, manage a drug-interaction window (especially with nitrates, see below), or interpret pharmacokinetic measurements in a follow-up study.

The 17.5-hour half-life also means accumulation occurs with daily dosing. Daily 5 mg dosing produces a steady-state plasma trough that is approximately 1.6-fold higher than the trough after a single 5 mg dose, because the next dose lands before the previous one is fully eliminated. This is the molecular basis for the “low-dose continuous” pattern that distinguishes tadalafil from the shorter-acting PDE5 inhibitors: at 2.5 mg or 5 mg once daily, plasma levels stay within a narrow band rather than swinging between peak and trough.

Dosing: 2.5/5/10/20 mg

The published clinical literature describes two distinct dosing patterns for tadalafil. They are not interchangeable, and they reflect different research designs.

Once-daily low-dose (2.5 or 5 mg). This pattern is built around the long half-life. A daily dose maintains steady-state plasma concentration above the threshold for clinically meaningful PDE5 inhibition continuously, eliminating the need to time the dose around an activity window. According to PubMed, three randomized, double-blind, placebo-controlled multicenter trials demonstrated that once-daily tadalafil at 2.5, 5, and 10 mg was significantly superior to placebo across validated measures of erectile function, with the 5 mg dose carrying the most favorable benefit-to-tolerability ratio (Porst et al., 2009, PMID 19756466, DOI).

On-demand (10 or 20 mg). This pattern is built around the 36-hour activity window. A single dose taken approximately 30 minutes to 2 hours before activity covers a window that extends well past the duration of activity, providing flexibility on timing. The 20 mg dose is the highest approved on-demand dose in regulatory monographs.

A randomized phase II trial directly compared the two patterns in a clinically defined population. Patients with post-radiotherapy ED were randomized to either on-demand 20 mg or once-daily 5 mg tadalafil for 12 weeks. Both regimens produced significant improvements across all International Index of Erectile Function (IIEF) domains. Treatment compliance was higher in the once-daily 5 mg arm (100 percent versus 86 percent), and there was a non-statistically-significant trend toward fewer adverse events in the daily-dose arm (Ricardi et al., 2010, PMID 21711479, DOI).

A separate trial examined a combination approach, randomizing patients to once-daily 5 mg tadalafil alone or once-daily 5 mg tadalafil combined with on-demand sildenafil 50 mg. The combined regimen produced larger improvements in IIEF-5 scores in patients with severe baseline ED, with no difference in adverse events between the two arms (Cui et al., 2014, PMID 24387078, DOI).

The choice between dosing patterns in research design depends on the question being asked. A dose-response study aimed at characterizing peak-effect pharmacodynamics is best answered by an on-demand 20 mg arm because the peak plasma concentration is the relevant exposure. A study of long-term endothelial function or biomarker drift is better answered by a daily-dose 5 mg arm because the steady-state plasma concentration is the relevant exposure.

For a deeper dose-tier breakdown, including 2.5 mg, 5 mg, 10 mg, and 20 mg parameters and protocol templates, see the tadalafil dosage guide.

Tadalafil vs sildenafil

The two most-prescribed PDE5 inhibitors are tadalafil and sildenafil, and the published comparative literature is dense. The key differentiators reduce to four parameters.

Half-life. Tadalafil 17.5 h, sildenafil 4 h. This is the dominant clinical difference and the basis for tadalafil’s once-daily-dosing label. Sildenafil’s shorter half-life requires per-event dosing in nearly all clinical contexts.

Onset. Sildenafil 30 to 60 minutes, tadalafil approximately 2 hours. For research designs that require a defined time-to-effect window, sildenafil’s faster onset can be the deciding factor.

Food sensitivity. Sildenafil’s absorption is meaningfully reduced by a high-fat meal, requiring a fasted-stomach administration window for predictable pharmacokinetics. Tadalafil’s absorption is not affected by food.

Selectivity profile. Sildenafil has measurable PDE5/PDE6 cross-affinity, producing transient visual symptoms in a subset of users. Tadalafil has measurable PDE5/PDE11 cross-affinity, producing back pain and myalgia in a subset of users. Neither cross-reactivity rises to a safety concern at approved doses, but the side-effect texture differs (Corbin and Francis, 2002, PMID 12166544; Wang et al., 2013, PMID 23937247, DOI).

For the full head-to-head comparison, including efficacy data, side-effect incidence rates, and population-specific recommendations, see tadalafil vs sildenafil.

Side-effect profile

The adverse-event profile of tadalafil has been characterized in pooled analyses of phase II and phase III randomized trials. The most comprehensive long-term safety pool integrates 12 randomized double-blind trials of tadalafil 5 mg once daily in men with LUTS/BPH or ED, totalling more than 1,800 patients, including a sub-population aged 75 years and older. According to PubMed, no clinically relevant differences in long-term tolerability were observed between younger and older men, and there was no signal of increased cardiovascular adverse events in older patients on tadalafil 5 mg daily compared to placebo (Oelke et al., 2017, PMID 27988986, DOI).

The published incidence ranges for the most common adverse events are summarized below.

Adverse event	Approximate incidence	Notes
Headache	10 to 15%	Most common AE; typically mild to moderate; usually resolves with continued dosing
Back pain or myalgia	3 to 7%	More common with tadalafil than other PDE5 inhibitors; PDE11 cross-affinity is the leading mechanism hypothesis
Flushing	3 to 5%	Vasodilation-related; transient
Dyspepsia	2 to 4%	Smooth-muscle effect on lower esophageal sphincter
Nasal congestion	1 to 3%	Vasodilation-related
Visual disturbances	<1%	Less common than with sildenafil; PDE6 cross-affinity is the mechanism

Less common adverse events that warrant attention in a research context:

• Non-arteritic anterior ischemic optic neuropathy (NAION). Spontaneous reports of NAION in PDE5-inhibitor users were first surfaced in 2005. According to a Canadian Journal of Urology review of the literature published in 2006, fewer than 50 cases of NAION associated with PDE5 use had been reported to the U.S. Food and Drug Administration and 5 cases to Health Canada at the time of review. Causal attribution remains difficult because NAION shares its primary risk factors (age over 50, dyslipidemia, diabetes, hypertension, smoking) with the cardiovascular disease that frequently accompanies erectile dysfunction. The recommendation in the literature is informed-consent disclosure of the low risk and immediate cessation if vision changes occur (Bella et al., 2006, PMID 17076943).

• Sudden sensorineural hearing loss. Spontaneous reports led to a 2007 FDA label update for the PDE5 inhibitor class. The signal is rare and the causal relationship is debated, but immediate cessation and otologic evaluation are recommended if hearing loss occurs.

• Priapism. Erections lasting more than 4 hours require urgent medical evaluation. Priapism is dose-related and rare at approved doses.

For the granular adverse-event breakdown, including dose-response curves and management guidance per AE class, see tadalafil side effects.

BPH/LUTS use case

Tadalafil 5 mg once daily is the only PDE5 inhibitor approved by the U.S. Food and Drug Administration for the treatment of signs and symptoms of benign prostatic hyperplasia. The mechanistic rationale is the expression of PDE5 in prostatic and detrusor smooth muscle. PDE5 inhibition produces smooth-muscle relaxation in the prostatic urethra, prostate gland, and bladder neck, mirroring the cavernosal mechanism that drives the ED indication.

According to PubMed, dose-ranging and confirmatory studies that supported regulatory approval demonstrated that 12 weeks of once-daily tadalafil 5 mg produced statistically significant improvements in the total International Prostate Symptom Score (IPSS), the Benign Prostatic Hyperplasia Impact Index (BII), IPSS subscores, IPSS quality-of-life scores, and the International Index of Erectile Function. Improvements occurred regardless of patient age, prior alpha-blocker exposure, baseline LUTS severity, or coexisting ED status (Carson et al., 2014, PMID 24341303, DOI).

A 2024 randomized trial extended the BPH evidence base by comparing combination regimens. Patients with prostate volume greater than 40 mL and IPSS greater than 7 were randomized to either tamsulosin/finasteride or tadalafil/finasteride for 12 weeks. Both combinations produced significant improvements in IPSS and IPSS-QoL. The tamsulosin combination produced better average flow rates at week 4. The tadalafil combination produced significant improvements in IIEF erectile function scores while the tamsulosin combination significantly reduced all IIEF domains, identifying the trade-off researchers and clinicians should consider when matching therapy to a patient with concurrent BPH and ED concerns (Tawfik et al., 2024, PMID 38308714, DOI).

The pooled long-term safety analysis discussed in the side-effect profile section above confirms tolerability of once-daily 5 mg tadalafil in BPH/LUTS populations, including in men aged 75 years and older (Oelke et al., 2017, PMID 27988986, DOI).

Drug interactions and contraindications

Tadalafil’s interaction profile is dominated by two drug classes (one absolute, one relative) and one CYP3A4-related pharmacokinetic concern.

Absolute contraindication: organic nitrates. Co-administration of any PDE5 inhibitor with an organic nitrate (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) can produce profound, potentially life-threatening systemic hypotension. The mechanism is additive vasodilation: nitrates donate NO, which activates the same cGMP pathway that PDE5 inhibition prolongs. The two effects do not summate linearly. They potentiate each other. According to a clinical review of PDE5 inhibitor cardiovascular interactions, the contraindication is absolute and applies regardless of the route of nitrate administration (oral, sublingual, transdermal, intravenous) (Doumas et al., 2015, PMID 25392015, DOI).

The 17.5-hour half-life makes the contraindication windowed: emergency nitrate administration after recent tadalafil exposure should be deferred for at least 48 hours from the last tadalafil dose unless the clinical situation requires immediate nitrate use, in which case close hemodynamic monitoring is mandatory. The 48-hour window is approximately three half-lives, which corresponds to roughly 87 percent plasma clearance of the parent drug.

The contraindication extends to recreational alkyl nitrites (“poppers”), which are pharmacologically equivalent to organic nitrates for the purpose of this interaction.

Absolute contraindication: riociguat. Riociguat is a soluble guanylate cyclase (sGC) stimulator approved for pulmonary hypertension. It activates the same cGMP pathway from upstream of PDE5, and its co-administration with a PDE5 inhibitor produces additive vasodilation analogous to the nitrate interaction.

Relative interaction: alpha-blockers. Alpha-1 adrenergic receptor antagonists (tamsulosin, alfuzosin, doxazosin, terazosin) lower blood pressure through smooth-muscle relaxation in the vasculature, prostate, and bladder. Co-administration with tadalafil can produce additive hypotension, particularly with the non-selective alpha-blockers (doxazosin, terazosin). The interaction is dose- and time-dependent; with the prostate-selective tamsulosin and alfuzosin, co-administration is generally well tolerated at standard tadalafil doses, and the combination is in fact a routine clinical pattern in BPH management.

Pharmacokinetic interaction: CYP3A4 substrates. Tadalafil is metabolized predominantly by CYP3A4. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, certain macrolide antibiotics) can substantially elevate tadalafil plasma exposure, requiring dose reduction. Strong CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, St. John’s Wort) reduce tadalafil exposure. Grapefruit juice, a moderate CYP3A4 inhibitor, can produce a modest exposure increase, though the effect is smaller than for some other CYP3A4 substrates (Corbin and Francis, 2002, PMID 12166544).

For population-specific guidance and dose-adjustment templates, see tadalafil protocol and tadalafil side effects.

Regulatory status in Canada

Tadalafil is a Schedule F prescription drug in Canada under the Food and Drug Regulations, meaning it is not legally distributable for human use without a prescription from a licensed practitioner. Health Canada has approved tadalafil under multiple Drug Identification Numbers (DINs) for the treatment of ED at on-demand and once-daily doses, BPH-related LUTS, and pulmonary arterial hypertension under the Adcirca brand at higher doses.

For Canadian researchers, tadalafil sourced through the regulated pharmaceutical supply chain (a pharmacy filling a valid prescription) is governed by the Schedule F prescription requirement. Tadalafil sourced as a research compound, outside the DIN-regulated pharmaceutical channel, is governed by laboratory and in vitro research compound framing. Elite Bio Supply distributes tadalafil under the research compound framing only. Nothing on this page is medical advice, and tadalafil distributed by Elite Bio Supply is not for human consumption.

The legal-status framing, including the difference between Schedule F prescription requirements and research-compound sourcing, is covered in greater depth at is tadalafil legal in Canada?.

Sourcing and quality verification

Elite Bio Supply distributes tadalafil through a sourcing model that reflects the Canadian research-compound supply channel. The model has three operational layers:

1. Verified pharmaceutical manufacturer at the source. Each tadalafil batch is sourced from a manufacturer with documentation of production. The batch carries source-level identification.
2. Batch identification on the dispatched product. Each retail unit is blister-packed with batch ID, allowing traceability back to the source batch.
3. Pre-dispatch inspection. Each batch is visually inspected for blister integrity, labelling, and packaging before fulfillment.

Per-batch independent third-party certificate of analysis (COA) testing is on the development roadmap and not part of the current sourcing model. Claims of per-batch ISO 17025 third-party testing are not made by Elite Bio Supply at this time. The current quality-verification chain and the roadmap to per-batch COA testing are documented in detail at how Elite Bio Supply verifies product quality.

For the commercial product page, including pack size, current pricing, and shipping logistics within Canada, see buy tadalafil in Canada (20 mg).

Frequently asked questions

What makes tadalafil different from sildenafil?
Tadalafil’s elimination half-life is approximately 17.5 hours, compared to sildenafil’s 4 hours. The longer half-life enables both as-needed dosing with a wider efficacy window and a daily-low-dose protocol that maintains steady plasma concentrations.

What dosage range is studied in research?
Published research protocols use 2.5 mg or 5 mg daily for steady-state dosing, or 10 mg to 20 mg as-needed before activity. The 20 mg dose is the highest approved on-demand dose in regulatory monographs.

Is tadalafil a controlled substance in Canada?
Tadalafil is Schedule F in Canada, meaning it requires a prescription for human use. Elite Bio Supply ships tadalafil for research compound only, not for human consumption. See the legal-status page for the full regulatory framing.

How long does tadalafil stay active?
Plasma concentrations remain therapeutic for approximately 36 hours after a 20 mg dose, which is why on-demand tadalafil is sometimes called “the weekend pill” in clinical literature. Daily-dose protocols maintain a continuous low-level plasma concentration without peak-trough swings.

What are the most common adverse events?
Headache (10 to 15 percent of trial participants), back pain and myalgia (3 to 7 percent, more common with tadalafil than other PDE5 inhibitors due to PDE11 cross-affinity), flushing (3 to 5 percent), and dyspepsia (2 to 4 percent). Vision and hearing changes are rare. Full safety profile is on the side-effects page.

Are nitrates a contraindication?
Yes. Absolute contraindication. Co-administration with organic nitrates (nitroglycerin, isosorbide) can produce profound hypotension and is potentially fatal. This contraindication extends to recreational nitrites (“poppers”) and applies for at least 48 hours after the last tadalafil dose due to the long half-life.

Can tadalafil be used for BPH?
Yes. 5 mg daily is approved for benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) in many regulatory jurisdictions. The mechanism overlaps with PDE5-mediated smooth muscle relaxation in prostatic and bladder tissue.

Where is tadalafil sourced?
Elite Bio Supply sources from verified pharmaceutical manufacturers with batch identification and pre-dispatch inspection. See the COA page for the full sourcing model and roadmap to per-batch third-party testing.

References

References sourced via PubMed. Tadalafil-specific literature in this guide.

---

Research use only. This content is for research and informational purposes; it is not medical advice and does not establish a doctor-patient relationship. Consult a licensed physician before any use that involves human consumption. Tadalafil is a Schedule F prescription drug in Canada.

Related reading

• Tadalafil dosage guide: 2.5/5/10/20 mg protocols
• Tadalafil protocol: ED, BPH, off-label endurance
• Tadalafil side effects in detail
• Tadalafil vs sildenafil: half-life and onset compared
• Is tadalafil legal in Canada?
• Buy tadalafil in Canada (20 mg)
• How Elite Bio Supply verifies product quality